AnaptysBio, Inc.
ANAB
$64.72
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 108.25M | 76.32M | 22.26M | 27.77M | 43.11M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 108.25M | 76.32M | 22.26M | 27.77M | 43.11M |
| Cost of Revenue | 25.56M | 31.41M | 37.82M | 41.18M | 42.59M |
| Gross Profit | 82.69M | 44.91M | -15.56M | -13.41M | 524.00K |
| SG&A Expenses | 15.79M | 10.21M | 10.61M | 14.13M | 10.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.35M | 41.62M | 48.43M | 55.31M | 52.78M |
| Operating Income | 66.90M | 34.70M | -26.17M | -27.54M | -9.67M |
| Income Before Tax | 49.70M | 15.11M | -38.59M | -39.29M | -21.79M |
| Income Tax Expenses | 81.00K | -- | 39.00K | 44.00K | -6.00K |
| Earnings from Continuing Operations | 49.61M | 15.11M | -38.63M | -39.33M | -21.78M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.61M | 15.11M | -38.63M | -39.33M | -21.78M |
| EBIT | 66.90M | 34.70M | -26.17M | -27.54M | -9.67M |
| EBITDA | 67.03M | 34.84M | -26.03M | -27.39M | -9.53M |
| EPS Basic | 1.79 | 0.54 | -1.34 | -1.28 | -0.72 |
| Normalized Basic EPS | 1.12 | 0.34 | -0.84 | -0.80 | -0.45 |
| EPS Diluted | 1.58 | 0.52 | -1.34 | -1.28 | -0.72 |
| Normalized Diluted EPS | 0.99 | 0.33 | -0.84 | -0.80 | -0.45 |
| Average Basic Shares Outstanding | -- | 27.83M | 28.81M | 30.64M | 30.45M |
| Average Diluted Shares Outstanding | 29.02M | 29.02M | 28.81M | 30.64M | 30.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |